Albert David Limited Stock Price Today (NSE: ALBERTDAVD)
Fundamental Score
Albert David Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Albert David Limited share price today is ₹860.45, up +1.00% on NSE/BSE as of 16 September 2026. Albert David Limited (ALBERTDAVD) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹491.08 (Cr). The 52-week high for ALBERTDAVD share price is ₹931.85 and the 52-week low is ₹579.90. At a P/E ratio of 21.77x, ALBERTDAVD is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of -0.38% and a debt-to-equity ratio of 0.07.
Albert David Limited Share Price Chart — NSE/BSE Historical Performance
Albert David Limited share price chart: 5.79% return over the past month. 52-week high ₹931.85, 52-week low ₹579.90.
Albert David Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹859.50 | ₹870.05 | ₹835.00 | ₹860.45 | 4.78K (Cr) | |
| ₹844.55 | ₹862.85 | ₹832.00 | ₹851.90 | 5.78K (Cr) | |
| ₹847.65 | ₹850.45 | ₹835.50 | ₹844.35 | 2.81K (Cr) | |
| ₹855.15 | ₹861.00 | ₹838.60 | ₹850.00 | 1.63K (Cr) | |
| ₹854.00 | ₹854.00 | ₹832.30 | ₹850.55 | 3.81K (Cr) | |
| ₹863.00 | ₹867.80 | ₹840.00 | ₹844.05 | 6.48K (Cr) | |
| ₹866.10 | ₹880.00 | ₹851.10 | ₹863.00 | 4.09K (Cr) | |
| ₹876.90 | ₹878.00 | ₹851.60 | ₹860.25 | 3.34K (Cr) | |
| ₹876.00 | ₹883.90 | ₹865.00 | ₹870.15 | 1.78K (Cr) | |
| ₹875.10 | ₹878.00 | ₹861.00 | ₹871.70 | 3.97K (Cr) |
Albert David Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹898.00 | ₹908.00 | ₹832.00 | ₹860.45 | -4.18% | |
| ₹691.75 | ₹931.85 | ₹685.55 | ₹897.90 | +29.80% | |
| ₹703.80 | ₹723.00 | ₹678.00 | ₹689.30 | -2.06% | |
| ₹710.10 | ₹737.95 | ₹683.50 | ₹699.25 | -1.53% | |
| ₹700.65 | ₹819.60 | ₹700.65 | ₹708.45 | +1.11% | |
| ₹605.00 | ₹769.80 | ₹602.15 | ₹715.40 | +18.25% | |
| ₹695.30 | ₹710.20 | ₹579.90 | ₹587.05 | -15.57% | |
| ₹696.65 | ₹779.00 | ₹678.30 | ₹711.55 | +2.14% | |
| ₹738.20 | ₹769.00 | ₹663.35 | ₹687.40 | -6.88% | |
| ₹790.00 | ₹801.35 | ₹731.00 | ₹736.60 | -6.76% | |
| ₹840.00 | ₹903.00 | ₹776.30 | ₹792.90 | -5.61% | |
| ₹785.80 | ₹866.45 | ₹775.00 | ₹849.90 | +8.16% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Albert David Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Albert David Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALBERTDAVD across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 21.77 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (303.12%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (43.60%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 3.40)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (62.24%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (-0.38%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.78%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Interest Coverage (1.20x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 2.23%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Albert David Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Albert David Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Albert David LimitedAlbert David Li...Selected✓ ALBERTDAVD • 524075 | 18.4/100 | ₹860.45₹860 | ₹491.08₹491.08 | 21.77Average 21.8 Average | -0.38%Poor -0.38% Poor | 0.78%Poor 0.78% Poor | 0.07Excellent 0.1 Excellent | — — | 6.16%Good 6.16% Good | 0.72% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1845.80₹1846 | ₹442862.79₹442862.79 | 36.62Average 36.6 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9392.00₹9392 | ₹248888.00₹248888.00 | 85.22Average 85.2 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4933.00₹4933 | ₹166962.32₹166962.32 | 78.80Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1377.50₹1378 | ₹111281.34₹111281.34 | 33.00Average 33.0 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1114.10₹1114 | ₹111187.18₹111187.18 | 24.83Average 24.8 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.60₹1942 | ₹104894.94₹104894.94 | 95.83Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1670.10₹1670 | ₹96097.55₹96097.55 | 26.10Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.20₹1144 | ₹95540.70₹95540.70 | 29.57Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2085.00₹2085 | ₹95336.63₹95336.63 | 17.23Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2256.40₹2256 | ₹93189.32₹93189.32 | 45.59Average 45.6 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price442862.79 Cr
- Divi's Laboratories Limited share price248888.00 Cr
- Torrent Pharmaceuticals Limited share price166962.32 Cr
- Cipla Limited share price111281.34 Cr
- Zydus Lifesciences Limited share price111187.18 Cr
Albert David Limited PE Ratio History
Historical price-to-earnings ratio for ALBERTDAVD — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹30.14 | ₹736.60 | 24.4x |
| FY 2024 | ₹132.15 | ₹1327.10 | 10x |
| FY 2023 | ₹63.39 | ₹975.35 | 15.4x |
| FY 2022 | ₹61.78 | ₹566.75 | 9.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Albert David Limited Dividend History
Annual cash dividends paid by ALBERTDAVD — dividend yield 0.72%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹6.55 Cr |
| FY 2024 | ₹5.17 Cr |
| FY 2023 | ₹5.15 Cr |
| FY 2022 | ₹3.44 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Albert David Limited Quarterly Performance
Latest quarterly metrics for ALBERTDAVD — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
43.60%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
303.12%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.16%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Albert David Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ALBERTDAVD — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Albert David Limited Financial Statements
Annual income statement, balance sheet and cash flow for Albert David Limited (ALBERTDAVD) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Albert David Limited
About ALBERTDAVD (Albert David Limited)
Albert David Ltd is a venerable pharmaceutical company with deep roots in the Indian healthcare landscape. Established in 1938, the Kolkata-based organization has cultivated a stro...ng reputation as a manufacturer and distributor of a diverse range of pharmaceutical products, catering to both domestic and international markets. Their portfolio spans a broad spectrum of therapeutic areas, showcasing a commitment to addressing a wide array of medical needs. From essential formulations to specialized treatments, Albert David Ltd strives to provide accessible and reliable healthcare solutions. This dedication to quality and patient well-being has solidified their position as a trusted partner for healthcare professionals and consumers alike. The company's product offerings encompass a variety of dosage forms, reflecting a sophisticated understanding of drug delivery systems and patient preferences. They are known for their expertise in manufacturing parenterals, ensuring the availability of critical medications for intravenous administration. Additionally, they provide oral and enteral formulations, offering convenient and effective treatment options for various conditions. Furthermore, Albert David Ltd extends its capabilities to topical agents, aerosol products, and specialized therapies, including products for gynecology, orthopedics, and vision care. This comprehensive approach demonstrates their commitment to innovation and meeting the evolving needs of the healthcare industry. Beyond conventional pharmaceuticals, Albert David Ltd also explores the potential of herbal medicine, developing herbal dosage forms that leverage the therapeutic properties of natural ingredients. This reflects a forward-thinking approach, embracing both modern science and traditional knowledge to create holistic healthcare solutions. Coupled with their focus on manufacturing bulk drugs, Albert David Ltd demonstrates a vertically integrated approach, ensuring control over the quality and supply chain of their products. Through their unwavering commitment to research, development, and manufacturing excellence, Albert David Ltd continues to play a significant role in shaping the future of healthcare.
Company Details
Key Leadership
ALBERTDAVD Share Price: Frequently Asked Questions
What is the current share price of Albert David Limited?
Albert David Limited (ALBERTDAVD) trades at ₹860.45 on NSE and BSE. Market cap ₹491.08 (Cr). Educational data only.
What is the P/E ratio of Albert David Limited?
Albert David Limited has a P/E of 21.77x vs industry average 34.89x.
What is the Bull Run score for Albert David Limited?
Albert David Limited has a Bull Run score of 18.4/100 based on 25+ financial parameters.
Does Albert David Limited pay dividends?
Albert David Limited has a dividend yield of 0.72%. Past dividends don't guarantee future payments.
What is the ROE of Albert David Limited?
Albert David Limited has ROE of -0.38%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Albert David Limited?
Albert David Limited has debt-to-equity of 0.07.
Is Albert David Limited a good investment?
Bull Run gives Albert David Limited a score of 18.4/100. This is not investment advice — consult a SEBI-registered advisor.